Search results
Author(s):
Maki Komiyama
Added:
2 months ago
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
1 year ago
Author(s):
Gheorghe-Andrei Dan
,
Antoni Martínez-Rubio
Added:
1 year ago
Myosin Inhibition in Non-obstructive HCM
Author(s):
Koji Hasegawa
,
Moritake Iguchi
,
Hiromichi Wada
,
et al
Added:
4 days ago
Viewpoint
Artificial Intelligence and AF
Author(s):
Davide Antonio Mei
,
Benedetta Cherubini
,
Jacopo Francesco Imberti
,
et al
Added:
1 month ago
Review Article
Author(s):
Varun Sundaram
Added:
1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
2 months ago
Source:
Arrhythmia Academy
A substudy of the ADVANTAGE AF trial has demonstrated that for treating typical atrial flutter (AFL), pulsed field ablation (PFA) is as effective and safe as conventional radiofrequency ablation (RFA), but significantly more efficient.¹ The study focused on adjunctive cavotricuspid isthmus (CTI) ablation, a common procedure performed during atrial fibrillation (AF) ablation.Mechanism of ActionPFA…
View more
Author(s):
Vivek Reddy
Added:
7 months ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then…
View more
SK Channels as a New AAD Target
Author(s):
Arnela Saljic
,
Jordi Heijman
,
Dobromir Dobrev
Added:
1 year ago
Review Article
Author(s):
Renato D Lopes
Added:
1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more